Data as of 15 November 2026. Expiry ahead.
What releases on 7 December 2026
| Expiry date | 7 December 2026 |
|---|---|
| Trigger, as stated in the filing | 12 months after offering |
| Shares released | 1,933,439 |
| Value at the latest close | $2M |
| Market capitalisation | $9M |
| Value / market cap | 22% |
| Absorb days | 40 |
| Exchange | NYSEAMERICAN |
| Sector | Healthcare |
| Offer price | $8.00 |
| Listed | 4 December 2025 |
| Latest close | $1.23 |
| Since the offer price | -84.6% |
Timing. Shares are released on a Sunday (Dec 6, 2026), so they typically become tradable on the next US market session.
How to read the two numbers that matter
Value / market cap measures the unlocking stock against the whole company. Absorb days is sharper: the unlocking shares divided by the stock’s own average daily volume over the last 20 sessions — how many normal trading sessions it would take the market to absorb the supply. A large unlock at a heavily traded company is a rounding error; a small one at a stock that barely trades is not. We mark a lock-up where the value reaches 25% of market capitalisation, or where absorbing it would take 50 sessions or more.
Where to look next
- Regentis Biomaterials (RGNT): Deep Value Biotech Opportunity or a Falling Knife After IPO Collapse? — our analysis.
Source. The expiry date, the trigger and the share counts are read from the company’s own SEC filing: Prospectus. Price, market capitalisation and the return since the offer price are as of 15 November 2026. Average daily volume is the last 20 sessions.
iposight.com — for informational purposes only. Nothing on this page is a recommendation to buy or sell.
